← All trials
NCT04460352
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2020
- Primary completion
- Sep 18, 2026
- Completion date
- Dec 31, 2031
- First posted
- Jul 7, 2020
- Last posted
- Dec 3, 2020
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Karolinska InstituteLead sponsor
- Karolinska InstituteReponsible party - principal investigator
- Karolinska InstituteStudy chair
- University of LeipzigCollaborator
- The Swedish Research CouncilCollaborator
- University of LeipzigStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.